Clinical Trial Update: FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial comparing FOLFIRI alone, FOLFIRI plus bevacizumab, and FOLFIRI plus E7820 as second-line therapy in locally advanced or metastatic colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• E7820
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Eisai Inc. | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-11-07